Vidasym, Inc

Biotech · Private

Novel vitamin D receptor modulators (VDRMs) for osteoporosis treatment with reduced hypercalcemic toxicity

Grants
$3.0M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
7
2 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Novel drug VS-105 for treatment of osteoporosis$1,480,983
Federal grantDepartment of Health and Human Services · Phase II · Novel drug VS-105 for treatment of osteoporosis$1,480,983
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3066490 BIOTECH INC——
3067Synthis Therapeutics, Inc.——
3068Ottimo Pharma——
3069Vidasym, Inc——
3070Arrowhead Pharmaceuticals——
3071XTEM PHARMACEUTICALS, INC.——
3072SENEB BIOSCIENCES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 7

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.